Fahad and Amol want you to recognize that:

1. Idarucizumab as an agent that specifically reverses the hemostatic effects of dabigatran. 

2. A post-hoc analysis of the ROCKET-AF study showed that digoxin is associated with increased mortality in patients with atrial fibrillation.

The papers

Idaracizumab for Dabigatran reversal.

Digoxin use and mortality in ROCKET-AF.

Good stuff

http://www.smacc.net.au/about-us/welcome/

http://emupdates.com/wp-content/uploads/2015/06/Strayer-Opioid-Misuse-SMACC-Slideset.pdf

Screening for occult cancer in unprovoked Venous Thromboembolism.

Perioperative bridging anticoagulation in Atrial Fibrillation